Breaking News

Financial Report: Baxter

April 17, 2014

Revenues up 15% boosted by Gambro acquisition

Baxter

1Q Revenues: $4.0 billion (+15%)

1Q Earnings: $556 million (+1%)

Comments: BioScience revenues were $1.6 billion, up 5%, driven by growth of ADVATE and FEIBA, improved U.S. sales of plasma-based therapeutics including GAMMAGARD LIQUID, and milestone payments related to ongoing collaborations with governments on flu vaccine development. Medical Products sales increased 22% to $2.3 billion, augmented by the Gambro acquisition, which contributed $400 million. R&D expenses were $313 million up 27%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks